Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
نویسندگان
چکیده
BACKGROUND In patients with multiple myeloma (MM), bortezomib is associated with a significant risk of Varicella zoster virus (VZV) reactivation. There are some reports that acyclovir reduces the risk of VZV reactivation. We assessed whether VZV reactivation could be reduced by using prophylactic valacyclovir at a dose of 500 mg daily. PATIENTS AND METHODS We retrospectively evaluated 32 patients with MM who received bortezomib and valacyclovir prophylaxis at the Kanazawa Medical University Hospital. Patients received valacyclovir prophylaxis orally at a dose of 500 mg daily, without cessation during bortezomib treatment. RESULTS The median age was 69 years (range=45-90 years). Fifteen patients were male and seventeen were female. The median bortezomib dose was 37.0 mg/m(2) (range=5.2-167.6 mg/m(2)). All patients also received corticosteroids. The median duration of valacyclovir prophylaxis was 301 days (range=24-1206 days) and the median valacyclovir dose was 150.5 g (range=12-603 g). VZV reactivation developed in only one patient during valacyclovir prophylaxis. VZV reactivation did not develop in three patients who had a past history of VZV reactivation without valacyclovir prophylaxis. Adverse events over grade 3 associated with valacyclovir were not observed. CONCLUSION Valacyclovir at a dose of 500 mg daily appears to be effective at preventing VZV reactivation and was well-tolerated by patients with MM who received bortezomib.
منابع مشابه
Bortezomib and bilateral herpes zoster.
Bortezomib is a proteasome inhibitor that has proven to be a very effective treatment for multiple myeloma. There is considerable debate about the potential for reactivation of the varicella zoster virus (VZV) in patients with multiple myeloma during treatment with bortezomib. This report describes the case of a 70-year-old patient with multiple myeloma that developed bilateral herpes zoster sh...
متن کاملCovid-19 Vaccination and Reactivation of Varicella Zoster Virus
Introduction: After COVID-19 pandemic in 2020 that mostly affects upper respiratory tract, the scientists investigated an effective vaccine against the virus. As the vaccination of general population started some patients were visited with varicella zoster virus activation following the COVID vaccine.
متن کاملThe Very Rare Concurrency of Herpes Zoster and Varicella in a 4-Year-Old Boy
Varicella is a common and worldwide disease in childhood. It causes primary (chickenpox) and latent infection that may lead to a reactivation disease called zoster (shingles). Zoster or shingles is caused by reactivation of the virus that has been latent in the spinal dorsal ganglion and may occur even in immunocompetent hosts. Although zoster is rare in children, it ma...
متن کاملLow-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study.
OBJECTIVE Acyclovir prophylaxis has been considered as mandatory for patients receiving bortezomib because herpes zoster is a common adverse event associated with the use of bortezomib. Although the minimal effective dose of acyclovir for prophylaxis has not yet established, the efficacy of low-dose acyclovir prophylaxis, 400 mg once daily, has been suggested. METHODS We retrospectively revie...
متن کاملClinical efficacy and tolerability of valacyclovir versus acyclovir in treatment of herpes zoster
Background: Acyclovir, a specific and selective inhibitor of replication of herpesviridae family, has well documented efficacy for speedy rash healing and decreasing pain of herpes zoster. Limited oral bioavailability of acyclovir requires frequent dosing. Valacyclovir is rapidly and almost completely converted to acyclovir in vivo and gives three to fivefold increase in acyclovir bioavailabili...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Anticancer research
دوره 32 12 شماره
صفحات -
تاریخ انتشار 2012